Cidara Therapeutics (Cidara Therapeutics) Debt-to-EBITDA : -0.20 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cidara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.30 Mil. Cidara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.58 Mil. Cidara Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-24.14 Mil. Cidara Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cidara Therapeutics's Debt-to-EBITDA or its related term are showing as below:

CDTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.28 Med: -0.17 Max: -0.04
Current: -0.2

During the past 11 years, the highest Debt-to-EBITDA Ratio of Cidara Therapeutics was -0.04. The lowest was -0.28. And the median was -0.17.

CDTX's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.39 vs CDTX: -0.20

Cidara Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Cidara Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Debt-to-EBITDA Chart

Cidara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.28

-0.11

-0.12

-0.04

-0.20

Cidara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.02	0.08	-0.09	-0.13	-0.20

Competitive Comparison of Cidara Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Cidara Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cidara Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Debt-to-EBITDA falls into.

Cidara Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cidara Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.3	+	3.577)	/	-24.365
	=	-0.20

Cidara Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.3	+	3.577)	/	-24.14
	=	-0.20

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Cidara Therapeutics (NAS:CDTX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cidara Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cidara Therapeutics (Cidara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

20D:Germany

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121

Website

https://www.cidara.com

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Executives

Leslie Tari	officer: Chief Scientific Officer	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison	officer: Chief Medical Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein	director, officer: President & CEO	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward	officer: CHIEF LEGAL OFFICER	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah	officer: CFO & CBO	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala	officer: Chief Medical Officer	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson	officer: Dir. of Finance & Controller	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston	director	C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder	director	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher	director	6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121